Raymond James Financial I... (RJF)
NYSE: RJF
· Real-Time Price · USD
167.23
0.77 (0.46%)
At close: Oct 03, 2025, 2:25 PM
0.46% (1D)
| Bid | 167.08 |
| Market Cap | 33.34B |
| Revenue (ttm) | 15.57B |
| Net Income (ttm) | 2.13B |
| EPS (ttm) | 10.2 |
| PE Ratio (ttm) | 16.4 |
| Forward PE | 14.17 |
| Analyst | Hold |
| Dividends | $2.45 |
| Ask | 167.38 |
| Volume | 340,714 |
| Avg. Volume (20D) | 1,057,133 |
| Open | 167.10 |
| Previous Close | 166.46 |
| Day's Range | 165.81 - 168.09 |
| 52-Week Range | 117.57 - 177.66 |
| Beta | 1.05 |
| Ex-Dividend Date | Oct 1, 2025 |
Analyst Forecast
According to 0 analyst ratings, the average rating for RJF stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsRaymond James Financial Inc. is scheduled to release its earnings on
Oct 22, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 weeks ago
-3.27%
Shares of banking and financial services stocks ar...
Unlock content with
Pro Subscription
1 month ago
+2.09%
Shares of banks and financial services stocks are trading higher amid broad market strength following the latest CPI report and after President Trump extended the tariff truce with China by 90 days.
1 month ago · https://thefly.com
Palvella Therapeutics initiated with an Outperform at Raymond JamesRaymond James initiated coverage of Palvella Therapeutics with an Outperform rating and $54 price target. The firm says the company is developing Qtorin rapamycin, a novel topical therapy designed to ...
